Direkt zum Inhalt
Merck

SML3060

Sigma-Aldrich

Panobinostat

≥98% (HPLC)

Synonym(e):

(2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide, LBH 589, LBH-589, LBH589, N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, NVP-LBH589

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

10 MG
83,10 €
50 MG
335,00 €

83,10 €


Auf LagerDetails


Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
10 MG
83,10 €
50 MG
335,00 €

About This Item

Empirische Formel (Hill-System):
C21H23N3O2
CAS-Nummer:
Molekulargewicht:
349.43
MDL-Nummer:
UNSPSC-Code:
12352200
NACRES:
NA.77

83,10 €


Auf LagerDetails


Bulk-Bestellung anfordern

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

CC1=C(CCNCC2=CC=C(/C=C/C(NO)=O)C=C2)C3=CC=CC=C3N1

InChI

1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+

InChIKey

FPOHNWQLNRZRFC-ZHACJKMWSA-N

Biochem./physiol. Wirkung

Orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor with anti-cancer efficacy in vitro and in vivo.
Panobinostat (LBH589) is an orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor (class I HDAC1/2/3/8 IC50 = 2.5/13.2/2.1/277 nM; IIA HDAC4/5/7/9 IC50 = 203/7.8/531/5.7 nM; IIB HDAC6/10 IC50 = 10.5/2.3 nM, IV HDAC11 IC50 = 2.7 nM) with anti-cancer efficacy in vitro and in vivo.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Inhalation

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

David I Sandberg et al.
Journal of neurosurgery. Pediatrics, 1-9 (2020-05-02)
Chemotherapy infusions directly into the fourth ventricle may play a role in treating malignant fourth-ventricular tumors. This study tested the safety and pharmacokinetics of short-term and long-term administration of MTX110 (soluble panobinostat; Midatech Pharma) into the fourth ventricle of nonhuman
Yang Zhang et al.
Frontiers in cell and developmental biology, 8, 652-652 (2020-08-15)
We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) malignancy. Our analysis of the TCGA cohort showed that a subset of pro-tumorigenic integrins, including α1β1
Shan Su et al.
Frontiers in microbiology, 11, 1584-1584 (2020-08-09)
Invasive fungal infections are an emerging problem worldwide, which bring huge health challenges. Candida albicans, the most common opportunistic fungal pathogen, can cause bloodstream infections with high mortality in susceptible hosts. At present, available antifungal agents used in clinical practice
Peter Atadja
Cancer letters, 280(2), 233-241 (2009-04-07)
The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins. The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition
Kenji Fujimoto et al.
Neuro-oncology advances, 2(1), vdaa084-vdaa084 (2020-08-15)
Polyglutamylation is a reversible protein modification that commonly occurs in tumor cells. Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin. Therefore, tumor cells with high polyglutamylation levels are supposed

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.